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Within the last decade understanding of the mechanis-
tic basis of itch has improved significantly, resulting in 
the development of several human surrogate models of 
itch and related dysesthetic states. Well-characterized 
somatosensory models are useful in basic studies in 
healthy volunteers, in clinical studies for diagnostic and 
segmentation purposes, and in pharmacological studies 
to evaluate the antipruritic efficacy of existing and no-
vel compounds. This review outlines recently introdu-
ced histamine-independent human models of itch, their 
mechanisms, their ability to induce clinically relevant 
phenomena, such as alloknesis, and the results obtai-
ned through their use. The article also introduces recent 
advances in the understanding of itch and provides an 
overview of the methods to assess experimentally-indu-
ced itch and associated manifestations. Major improve-
ments are warranted in the treatment of chronic pruri-
tus, and reliable human surrogate models are a valuable 
tool in achieving them, both for basic researchers and 
for clinicians. Key words: itch; pruritus; histamine; hista-
mine-independent; surrogate model; cowhage.
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Itch, also known as pruritus, is an unpleasant sensation 
that may prompt the sufferer to scratch the affected area. 
Itch may occasionally be dismissed as a minor nuisance, 
perhaps because everyone has experienced innocuous 
episodic itch (1–3). However, chronic pruritus (> 6 weeks 
(1)) profoundly impacts quality of life for the affected 
patients through disturbances relating to sleep, attention 
and sexual function (1, 4). Itch is associated with wide 
range of medical conditions, such as urticaria, atopic 
dermatitis (AD), psoriasis, primary biliary cirrhosis, and 
chronic renal failure, as well as several neurological, 
infectious, neoplastic, haematological, autoimmune, 
genetic and drug-induced conditions (5, 6). Moreover, 
due to a prevalence of approximately 10% and a largely 
suboptimal treatment regimen, chronic itch represents a 
significant socioeconomic burden (1). 
Within the last decade understanding of the neural 
and molecular structures facilitating the sensation of itch 
during normal and pathophysiological conditions has 
been greatly enhanced (7). Perhaps most prominently, 
a long-suspected (8, 9), histamine-independent itch 
pathway has been uncovered, accompanied by a range 
of new peripheral receptors (i.e. new in a pruritogenic 
context) (7, 10–12). Moreover, histamine has been refuted 
as key mediator of itch in most of the clinical conditions 
presenting with chronic pruritus, which is in agreement 
with the fact that these conditions are frequently refrac-
tory to treatment with antihistamines (1, 13–15). Hence, 
the present treatment options for itch, beyond targeting 
the underlying disorder, are suboptimal, and the area is 
characterized by evidence originating from case-series 
or small-scale trials. This means that, as opposed to pain 
management, knowledge of treatment responsiveness in 
different itch patient subgroups is scarce (1). The progress 
made in elucidating the possibly distinct, histamine-
independent itch modalities has sparked a new demand; 
the need for reliable human surrogate models. Such mo-
dels facilitate the mimicking of activity in specific itch 
pathways in healthy human volunteers and patients with 
itch, whereby an improved understanding of itch can be 
achieved and novel diagnostic tools, targets and strategies 
for new pharmacological interventions can be revealed 
in a timely manner. This mechanistic approach, of using 
translatable symptom-specific surrogate models, has been 
highly advantageous within the field of pain research in 
terms of bridging the bench-to-bedside gap and of spur-
ring the idea of mechanisms-based treatment (16, 17). 
The present review provides an overview of the 
methods used to assess experimentally induced itch and 
analytically outlines the recently introduced histamine-
independent human models of itch that have been re-
ported in the research literature. This review does not 
intend to encompass a comprehensive summary of the 
mechanistic or therapeutic aspects of itch, but instead 
refers to recent reviews pertaining specifically to these 
subjects (1, 7, 18, 19). 
ASSESSING EXPERIMENTALLY INDUCED ITCH
Experimentally induced itch provides the opportunity to 
study a particular itch pathway in a chosen anatomical 
location, while accurately assessing the quality, inten-
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sity, latency and duration of the acute itch, related no-
ciceptive and dysesthetic states and the potential asso-
ciated vasomotor aberrations. Perhaps most importantly, 
induction of itch in healthy volunteers improves the 
study of itch mechanisms, e.g. by functional magnetic 
resonance imaging (fMRI) or microneurography, and 
provides a shortcut for evaluating modulating factors 
or potential interventions (12, 20–22). Many of these 
modulatory factors, such as heat stimulation, cold sti-
mulation, transient receptor potential (TRP)-modulation 
and scratch stimulation, have been characterized in 
histaminergic models, but remain uninvestigated or 
sparsely evaluated in non-histaminergic models. 
Assessment of itch intensity and quality
With the exception of mechanically and electrically 
evoked itch, most human surrogate models produce 
itch lasting 5–15 min with a peak intensity rating eli-
cited between 1 and 3 min after induction. In the case 
of clinical, as well as experimentally, induced itch, the 
sensation frequently presents with one or more associa-
ted sensations, such as pricking or burning. The most 
common approach is to instruct the participating subject 
to separately rate the sensory qualities of itch, pricking 
and burning on a generalized labelled magnitude scale 
(gLMS), a visual analogue scale (VAS) or a numerical 
rating scale (NRS), frequently (every 10–30 s) upon itch 
induction (10, 12, 14, 23). This allows for a temporal 
overview of the itch and other sensory qualities and 
reporting of itch latency, peak, area under the curve, etc. 
Since most models of itch include some co-activation 
of nociceptors, sensations of pain and nociceptive dy-
sesthesias should be assessed. For example, in a study 
addressing gender differences in surrogate models of 
itch, Hartmann et al. (24) reported itch intensity as “% 
itch of burning pain”, i.e. as a ratio between the itch in-
tensity score and the burning pain intensity score (both 
recorded by VAS). Interestingly, the study revealed that 
women reported a disproportionally higher intensity of 
burning pain than their male counterparts, particularly 
after histamine-induced itch (24). 
Itch-related dysesthesias
Alloknesis. This is the itch analogue to the pain term 
“allodynia”, in which a normally non-painful stimulus is 
perceived as painful (25). As such, alloknesis describes 
the dysesthetic state in which otherwise non-pruritic 
stimuli, such as brush strokes or light touch applied 
by von Frey hair, provoke a sensation of itch (26, 27). 
Alloknesis is a feature occurring not only in experi-
mental models of itch, but also in many of the clinical 
conditions involving chronic itch, such as AD (28). 
Hyperknesis. This is the itch-related analogue to the noci-
ceptive state “hyperalgesia”, in which a normally painful 
stimulus is associated with an increased pain response. In 
hyperknesis an increased itch response (in terms of magni-
tude or duration) is elicited upon a normally pruritogenic 
or prickling stimulus, e.g. by means of von Frey hair or 
weighted pinprick stimulators (29, 30). An area of hyper-
algesia, including secondary hyperalgesia, to pinprick 
stimuli also occurs in response to cowhage- or histamine-
evoked itch, although this is modest compared with that 
of epidermal or topical capsaicin. In experimentally 
induced itch, alloknesis and hyperknesis can be assessed 
both within the immediate area of pruritogen applica-
tion and in the surrounding area, denoted “primary” and 
“secondary”, respectively (28). Typically, the secondary 
area of alloknesis and hyperknesis is mapped by slowly 
approaching the application area by marked stimulus 
points and a pre-determined individualized stimulus. 
Hyperknesis is most commonly assessed by the use of 
von Frey or pinprick stimulators and, as such, represents 
“punctuate” or “dynamic” hyperknesis, but principally 
the parameter could also be assessed with a pruriceptive 
substance injected in the vicinity of the itchy area. 
Upon itch induction alloknesis and hyperknesis 
spreads rapidly beyond the area of pruritogenic applica-
tion (see Fig. 1) (23, 31). Mechanistically, alloknesis 
and hyperknesis are suggested to be a consequence of 
sensitization of the spinothalamic tract neurones con-
veying pruritogenic input, by a period of increased firing 
from itch-sensing primary afferents. Subsequently, 
these spinal neurones will become responsive to conver-
gent input from Aβ primary afferents mediating touch 
(resulting in alloknesis) and additional itch-sensing 
primary afferents innervating the area surrounding the 
application site (resulting in hyperknesis) (28, 32–34). 
Induction of itch can also result in a moderate area of 
hyperalgesia, normally associated with induction of 
pain or inflammation, highlighting the overlap between 
nociception and pruritoception (31). In addition to the 
central mechanisms, injection of nerve growth factor 
has been shown to potentiate non-histaminergic itch and 
related mechanical hyperalgesia, suggesting peripheral 
sensitization of the primary afferents (34). In histamin-
ergic and cowhage-induced itch, alloknesis spreads far 
beyond the immediate area of application within mi-
nutes and can extend to an area upwards of 20–30 cm 
dependent on the methodological approach. Typically, 
the area of alloknesis is reported to be slightly larger af-
ter cowhage-induced itch than after histamine-induced 
itch (23, 31). While the spatial profile of alloknesis is 
frequently mapped in experimental studies of itch, the 
temporal profile is very sparsely investigated. 
Wheal and flare response
Flare is an increase in superficial perfusion normally 
assessed manually by recording the size of the affected 
area or by laser Doppler flowmetry, speckle contrast 
imaging/full-field laser perfusion imaging (FLPI) (Fig. 
1), spectrophotometry or by infrared thermography, 
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recording both flare size and intensity. Mechanistically, 
flare is a consequence of antidromic activation of ter-
minal branches of CMi-fibres leading to the release of 
the vasoactive substance calcitonin-gene related peptide 
and substance P, which are important in the initiation 
of mast-cell activity (11, 35). Flare is dependent on 
the extent to which CMi-fibres, characterized by large 
receptive fields, are stimulated and is a typical feature of 
histamine-dependent itch, while histamine-independent 
itch, e.g. induced by cowhage spicules, appears to 
provoke no or very subtle vasomotor aberrations (35). 
A wheal is a vascular leakage response to histamine, 
observed as a raised, often pale and circumscribed 
dermal oedema, caused by acute protein extravasation 
in the vascularized dermis. It is a cardinal response to 
application of histamine or introduction of any mast 
cell degranulation-provoking substance, such as al-
lergens (23, 36). Wheals with a diameter of ~0.5 to 2.5 
cm are common upon punctate or intradermal delivery 
of histamine (2–4, 23, 37, 38). Although cowhage spi-
cules produce minimal vasomotor responses they have 
occasionally been shown to cause micro-skin reactions 
of slight oedema or flare no larger than 1 mm2 (23). 
DEFINING HISTAMINE-INDEPENDENT ITCH
Since the terms “histamine-independent” and “non-
histaminergic” are essentially negative definitions it 
is necessary to recapitulate on histamine as an itch 
inducer. Moreover, histamine is by far the most-studied 
pruritogen, having been widely used as the prototy-
pical experimental proxy of itch and, hence, despite 
the focus of this review being histamine-independent 
itch modalities, histamine-induced itch deserves a 
brief mentioning. Mechanistically, histamine activates 
the H1-receptor (H1-R) present on CMi-fibres and 
co-localized with the heat thermo-receptor, transient 
receptor potential vanillin 1 (TRPV1) (39, 40). Upon 
binding of histamine to the H1-R, TRPV1 is activated 
by downstream signalling, leading to an influx of Ca2+, 
whereby the primary afferent initiates a pruritic signal. 
To induce itch, histamine can be applied epicuta-
neously in combination with iontophoresis, by epidermal 
penetration with a lancet or functionally inert cowhage 
spicules coated with histamine or as an intradermal 
injection (3, 9, 14, 27, 41–44). All routes of administra-
tion are shown to produce a moderate to strong sensa-
tion of spontaneous itch, with slight differences in the 
reported presence of nociceptive sensations, alloknesis, 
and hyperknesis (27, 37). In particular, when injecting 
histamine the induced response ratio between nocicep-
tion and itch appears to shift away from itch towards a 
more nociceptive sensation characterized by burning and 
pricking (15). Lastly, the use of histamine is accompanied 
by a significant wheal and flare reaction regardless of the 
route of administration (26, 35, 37, 42). Since histamine-
dependent itch relies on the TRPV1-channel, a handful 
Fig. 1. A series of typical vasomotor 
and dysesthetic responses to epidermal 
insertion of 3–4 cowhage spicules; 
“native”, capsaicin- or histamine-
pretreated, in an area ≈1 mm2 on the volar 
forearm. The 2 upper rows are obtained 
from a Moor Full-field Laser perfusion 
imager (FLPI-2, Moor Instruments, 
Axminster, UK) 10 min after spicule 
insertion. Note that the lowest row of arm 
charts represent the typical reported mean 
dispersion of alloknesis, pin hyperknesis 
and pinprick hyperalgesia in response to 
insertion of spicules with the denoted 
substances. The individual differences 
within these response parameters are 
considerable.
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of studies have investigated the ability of capsaicin to 
induce itch, bypassing the H1-R, using epidermal, pun-
ctate and intradermal delivery (23, 24, 37). In general, 
capsaicin evokes burning pain and widespread flare 
when injected intradermally, while it produces significant 
itch and weaker burning pain when applied via inert 
cowhage spicules (23, 24, 37). This relative unspecifi-
city of itch processing supports the notion of itch being 
conveyed in accordance with the selectivity theory, by 
a subpopulation of superficially residing itch-labelled 
afferents responding to pruritogens and algogens, such 
as capsaicin, while allowing the activation of the much 
larger population of TRPV1+ nociceptors by capsaicin, 
to override the itch signal (24, 45–47). Since the flare 
response following punctate histamine is significantly 
more pronounced than that of capsaicin, it is probable that 
TPRV1+ nociceptors, and not weakly capsaicin-sensitive 
histamine responsive itch fibres, are the primary facili-
tators (5). For practical purposes, in the experimental 
setting, a distinction between histamine-dependent and 
histamine-independent itch can be determined by show-
ing that pre-administration of topical antihistamine, such 
as doxepine, reduces the itch intensity (11, 15). 
Unlike histamine-dependent itch, histamine-indepen-
dent itch is thought to rely mainly on a subpopulation 
of mechano-heat-sensitive/polymodal c-fibres (CMH) 
incapable of producing the extensive flare that is cha-
racteristic for histamine-induced itch (11, 27). In the 
non-histaminergic pathways the key second messenger 
role is played by transient receptor potential cation chan-
nel, subfamily A, member 1 (TRPA1), a downstream 
target of proteinase-associated receptor 2 (PAR) and 
Mas-related G-protein coupled receptor member G-
signalling (Mrgpr) (48–50). TRPA1 appears to be 
crucial, not only in conveying chronic itch sensation, 
but also in processes such as neurogenic inflammation, 
epidermal hyperplasia and altered gene expression in 
sensory nerves, which frequently accompany chronic 
itch conditions (48, 51). It was recently shown that itch 
and neurogenic inflammation can be induced in human 
skin by direct TRPA1-stimulation using the natural 
agonist trans-cinnamaldehyde (52). Lastly, a notable 
difference is present between histaminergic and non-
histaminergic itch in terms of higher processing. While 
both itch qualities activate brain structures such as tha-
lamus, primary and secondary somatosensory cortices 
and cingulate cortices, histamine-independent itch was 
additionally associated with activation of areas such as 
the insular cortex, claustrum and basal ganglia (21). In 
a recent study it was shown that activation of nucleus 
accumbens and the septal nuclei mediated through the 
mixed action κ- and μ-opioid, butorphanol, completely 
abolished histaminergic itch, while only modestly re-
ducing non-histaminergic itch, demonstrating that both 
peripheral and central processing differ between these 
itch pathways (20). 
HUMAN SURROGATE MODELS OF ITCH 
Non-chemical surrogate models of itch
Electrically-evoked itch. A few studies have explored the 
opportunity of using transcutaneous electrical stimula-
tion to induce itch, with varying success (10, 53, 54). 
Ikoma et al. (10) explored numerous electrical stimuli 
paradigms designed to produce itch, and found that a 2 
ms, 50 Hz, 0.05 mA stimulation with a 0.1×7 mm elec-
trode, induced a highly selective sensation of moderate 
itch rated ≈ 3 on a NRS (VAS 0–10), while increasing the 
current intensity to 0.12 mA produced the most intense 
itch sensation, 4.5 (VAS 0–10). At this higher intensity 
level, itch occurred alongside a modest level of pain at 2.2 
(VAS 0–10). Electrically induced itch was accompanied 
by very little axon reflex flare, in comparison than 1% 
histamine-iontophoresis, suggesting that it is not medi-
ated by histamine-sensitive CMi-fibres (10). Electrically 
evoked itch was also associated with a significantly larger 
area of alloknesis, than histamine, thus displaying a pat-
tern of effects similar to cowhage-induced histamine-
independent itch. Interestingly, the extent of the area of 
alloknesis exhibited a significant negative correlation 
with the pain intensity (10). 
A study designed to explore so-called “heterotopic 
pruritic conditioning” to itch as an analogue to “diffuse 
noxious inhibitory control” (DNIC) in pain used a sti-
mulus paradigm of 0.3 ms, 100 Hz with a 3.5 cm diam-
eter electrode, and determined the test stimulus intensity 
as 300% of the individually perceived unpleasantness 
threshold. For the conditioning stimulus the study app-
lied 0.5% histamine delivered by iontophoresis, which 
produced a mean itch intensity of 2.5 ± 2.0 in the healthy 
control group and 2.9 ± 2.5 in patients with psoriasis. Of 
more concern is the fact that the electrical test stimuli 
evoked surprisingly low and variable itch levels at ~1.5 
and ~0.55 (VAS 0–10) in healthy controls and psoriasis 
patients, respectively (54). This conditioning stimulus 
intensity is very low in comparison with the conditio-
ning stimuli applied in various pain studies, with oth-
erwise equivalent stimulus-test paradigms, to achieve 
a significant conditioned pain modulation-effect (55). 
Mechanically-evoked itch. Apart from the above-men-
tioned electrical approach, itch can also be induced non-
chemically with the use of mechanical stimulation. In a 
recent study, micro-vibration of the facial vellus hairs in 
a stimulus paradigm of 0–1 mm probe amplitude, at 1–50 
Hz for 90 s resulted in a mean peak itch intensity at 5 
(VAS 0–10). The chin was by far the most sensitive loca-
tion, while the cheek and the forehead were considerably 
less responsive (both ~ 2.5, VAS 0–10), and stimulation 
on the forearm did not produce any itch. The mechani-
cally evoked itch was unresponsive to antihistamine and 
did not entail flare or nociceptive sensations at any stimuli 
intensity, making the itch model unique. As opposed to 
mechanically evoked itch, histamine-induced itch was 
Acta Derm Venereol 95
775Human models of itch
significantly more pronounced on the forearm compared 
with any facial areas, suggesting that the neural facilita-
tion of itch may exhibit significant pathway heterogeneity 
depending on anatomical location (56). 
Proteinase-activated receptor 2/4 (PAR) mediated itch
Cowhage spicules. The spicules found on the pod of 
the leguminous plant cowhage (Mucuna pruriens) and, 
more importantly, the sensory effects that these induce 
when inserted into the epidermis, were described in 
1953 by Broadbent, who wrongfully concluded their 
itch inducing properties to be a consequence of an 
unknown substance causing histamine release (57). A 
few years later, Shelley & Arthur isolated mucunain, 
identified it as a proteinase, suggested it to be the 
principal itch-inducing compound in cowhage, and 
reported that the itch sensation it induced was “very 
unlike that of histamine” (8, 58). Fast-forward 50 years, 
the histamine-independent, PAR2/4 pathway of itch is 
uncovered, mucunain is revealed as a ligand of PAR2 
and PAR4 (59), and the interest in using cowhage as a 
human experimental model of itch rapidly re-emerges 
(11, 14, 22–24, 31, 34, 37, 58). The quality of the so-
matosensory effects associated with PAR2-activation, 
e.g. through insertion of cowhage spicules, have been 
described as very similar to those reported in patients 
with AD (14, 58). Moreover, the level of the endoge-
nous PAR2 agonist, tryptase, exhibits a 4-fold increase 
in serum from patients with AD, and expression of 
PAR2 on the primary afferent nerve fibres is markedly 
increased in skin biopsies from patients with AD, in-
dicating that the receptor is probably involved in the 
somatosensory aberrations of AD (60).
Cowhage spicules are 1–3 mm in length, with a dia-
meter of 1–3 µm at their tip. Inserted into the epidermis 
the spicules evoke a moderate to intense sensation of 
itch and, to a lesser extent, sensations of burning and 
stinging pain (11, 23, 61, 62). It has been reported that, 
in a majority of cases, a single spicule, estimated to oc-
cupy a skin area of  ≈ 0.00003 mm3, is sufficient to induce 
pruritic, nociceptive and dysesthetic sensations lasting 
4–10 min (see Table SI1). The insertion of cowhage 
spicule(s) rapidly and consistently produces alloknesis, 
hyperknesis and hyperalgesia far beyond the immediate 
area of application, but no or very little flare, presumably 
due to the lack of CMi-fibre activation (12, 22). 
Conveniently, cowhage spicules can be rendered 
functionally inert by heating and subsequently coated 
with another active compound, such as histamine or 
capsaicin. Hence, cowhage can serve as a convenient 
vehicle allowing delivery of any substance of interest to 
a very limited population of the most superficially resi-
ding nerve endings (15, 23, 31). However, the cowhage 
model has several drawbacks, e.g. the pods or spicules 
are often obtained from completely uncontrolled, un-
standardized sources and numerous papers in the field 
completely fail to mention how or from where the pods 
were obtained. The content of the active itch-inducing 
cysteine protease mucunain could potentially differ 
widely between habitats and time of harvest. These 
problems collectively hamper the comparability of 
studies utilizing the model and the reproducibility of 
the results achieved. A potential solution to this pro-
blem could be to extract mucunain and use it in known 
concentrations via injections or on reconstituted inert 
spicules, as done by Reddy et al. (59), although good 
manufacturing practice requirements related to human 
use could make this approach laborious. 
Other proteinases. The use of various proteinases, such 
as papain and tryptase, has been attempted to mimic 
non-histaminergic itch (58, 60, 62). The results are 
relatively sparse and variable. Arthur & Shelley con-
ducted a comprehensive study, administering numerous 
proteases by means of inert cowhage spicules and 
intradermal injections. Here, papain was found to be 
the most effective itch inducer of 48 tested enzymatic 
substances (63). More recently, papain administered 
by intra-cutaneous injection was shown to produce 
highly variable responses, i.e. of 33 experiments in 8 
subjects, 15 responded with itch and pain, 9 responded 
with itch, 2 responded with pain only, and 7 reported no 
evoked sensations (see Table SI1). Moreover, 13 of the 
33 experiments resulted in significant flare. Itch-related 
dysesthesias were not assessed (27, 58). 
Based on sparse evidence, papain primarily produces 
reliable itch upon intra-epidermal application. In the 
light of the variability and scarceness pertaining to the 
results on papain and importantly, recent studies on 
cowhage as a model of PAR2-dependent non-histamin-
ergic itch, proteases such as papain pose a somewhat 
redundant opportunity as a model of itch.
Mas-related G-protein coupled receptor-mediated itch 
(Mrgprs)
Mrgprs are a family of approximately 50 receptors, 
of which several are exclusively expressed on small 
diameter dorsal root ganglia neurones. In humans 
these include MrgprX1, a receptor for chloroquine and 
bovine adrenal medulla 8–22 peptide (BAM8-22), and 
MrgprD, which is restricted to axons innervating the 
epidermis and is responsive to the itch-inducing amino 
acid; β-alanine (64–66). 
Cellular and behavioural experiments have confir-
med BAM8-22, a derivative of proenkephalin A, as an 
agonist of MrgprC11 (and hMrgprX1) (15, 66, 67). In 
healthy human volunteers, BAM8-22 induced an itch 
intensity profile peaking at “moderate” on a gLMS ac-
companied by almost equally intensely rated pricking/1http://www.medicaljournals.se/acta/content/?doi=10.2340/00015555-2146
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stinging sensation and weak burning sensations, not 
unlike that evoked by active cowhage (see Table SI1). 
Insertion of BAM8-22-soaked spicules evoked very 
similarly sized areas of alloknesis, hyperknesis and 
hyperalgesia, of approximately 10 cm2, on average, and 
no wheal or flare. In accordance with the latter obser-
vation, the pruritic effect of BAM8-22 was shown to 
be completely histamine-independent, since it was not 
affected by antihistamine pretreatment. It remains to be 
elucidated whether the pruritic effect of BAM8-22 shifts 
towards algogenic if injected into the dermis, analogous 
to that of capsaicin, which is also pruritogenic when 
administered solely to the superficial pruritoceptive 
nerve terminals by spicules (15).
Similarly, β-alanine has been used as a model of 
itch by intradermal injection of 10 μl vehicle with 
22.5–180 μg of dissolved β-alanine. This produced a 
weak to moderate sensation of itch, accompanied by 
slight pricking/stinging and weak burning sensations. 
All reported sensations were present when injecting 
the similar, but inactive, amino acid L-alanine, albeit 
at a much lower intensity and only in a subgroup of vo-
lunteers (68). No wheal or flare was present indicating 
histamine-independency. Potential dysesthesias were 
not recorded. Both itch induced through MrgprX1 and 
MrgprD with BAM8-22 and β-alanine, respectively, are 
histamine-independent and appear to evoke a similar, 
but perhaps slightly weaker, pattern of sensory qualities 
than those elicited by cowhage (15, 31, 68). 
Itch induced by algogens: serotonin, bradykinin and 
substance P
Although being an established endogenous algogen 
the neurotransmitter serotonin has been shown to be a 
pruritogen in both healthy individuals and in patients 
with AD, and is suspected to play a role in the chronic 
pruritus often associated with cholestasis (69) and poly-
cythemia vera (70, 71). However, the mechanistic basis 
of serotonin-induced itch remains unclear (72). In a 
study by Hosogi et al. (73) serotonin at a concentration 
of 17 mg/ml was delivered by iontophoresis and caused 
intense histamine-independent itch in lesional skin of 
patients with AD and in skin of healthy controls. In ad-
dition, serotonin elicited a significant axon-reflex-flare, 
but no wheal response in both lesional and non-lesional 
skin, indicating that serotonin induces itch distinct 
from that evoked by activation of histamine, PAR2 
and Mrgpr receptors. In another study, iontophoretic 
delivery of serotonin (1%), induced moderate itch, a 
very large area of alloknesis, a large area of flare and, 
similar to other reports, no wheal. Thomsen et al. (74) 
found that intradermal injections of serotonin (0.25 
mg/ml) elicited moderate to strong itch only in normal 
skin, but not in experimentally induced eczematous 
skin in healthy volunteers. Rausl et al. (72) found that 
healthy controls and patients with AD differed only 
in their vasomotor response to serotonin injections, in 
contrast to the results of Hosogi et al. (73).
The classic algogen substance P has been used to 
induce itch in healthy controls and patients with itch 
conditions, such as AD (73–75). As for serotonin, results 
exhibited some inconsistency. For instance, intradermal 
substance P has been found to induce a stronger itch than 
histamine in both normal and eczematous skin, while 
substance P delivered iontophoretically induced very 
little itch in normal skin, but significantly more intense 
itch in lesional skin of patients with AD. In addition, the 
vasomotor and somatosensory effects of substance P app-
lication can be abolished by anti-histamine pretreatment, 
suggesting the mechanism of substance P-induced itch to 
be histamine-dependent (73, 76). Dysesthetic responses, 
such as alloknesis and hyperknesis, have not been asses-
sed in response to administration of substance P. 
Lastly, the vasodilatory peptide bradykinin has been 
sparsely assessed for pruritogenic properties (73, 77). 
Interestingly, iontophoretic application of the peptide 
appears to produce little or no itch in healthy skin and 
in non-lesional skin of patients with AD, but induced 
considerable itch in lesional skin of patients with AD 
without evoking vasomotor responses (73). 
CONCLUSION AND FUTURE PERSPECTIVES
Itch is a multifaceted sensation and although the gene-
ral discourse mainly deals with histaminergic and non-
histaminergic itch (11, 12, 78), more sub-classifications 
could be beneficial. Nakagawa & Hiura (18) suggested 
4: (i) a TRPV1+ histaminergic pathway; (ii) a TRPV1-
independent histaminergic pathway (since histamine-
induced itch is not completely abolished in TRPV1 
knock-out mice); (iii) a PAR2/4- and Mrgpr-mediated 
non-histaminergic pathway; and (iv) a serotonin-
mediated non-histaminergic pathway. However, it is 
currently indiscernible whether the multiple receptors 
mediating non-histaminergic itch are in fact associated 
with the same subpopulation of mechano-sensitive af-
ferents or whether distinct pathways exist. Moreover, 
it is also unclear to what extent itch processing could 
differ between various anatomical locations; a notion 
that was recently rekindled (44, 55, 79). Beyond the 
complexity posed by the multiple neural pathways and 
peripheral receptors mediating itch, the sensation is 
also strongly modulated by other somatosensory sub-
modalities, such as innocuous warmth, which facili-
tates itch, and pain and cold, which inhibit itch. These 
modulatory factors including their available chemical 
proxies, e.g. TRPM8-stimulation by l-menthol, have 
been investigated in relation to histamine-dependent 
itch, but not in a non-histaminergic context. 
The fact that multiple parallel pathways can convey 
the sensation of itch in healthy individuals and in patients 
with chronic pruritus constitutes a challenge as well as 
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an opportunity. On the one hand it complicates surrogate 
modelling and pharmacological development directed at 
itch, but on the other hand it could allow for increased 
diagnostic segmentation of itch-associated conditions 
and targeted therapy. This requires that the candidate 
mechanisms underlying itch must be validated in vari-
ous different clinical itch disorders by psychophysical 
studies, assessment of biopsies, targeted interventional 
studies, microneurograhic studies and the use of valida-
ted surrogate models in patients. Currently, sparse and 
ambiguous evidence exists in relation to whether patients 
with chronic itch or subgroups within this population 
experience peripheral or central sensitization to itch, 
comparable with what has been shown repeatedly in 
patients with chronic pain (14, 43, 53, 72). 
The development of diagnostic tools to aid clinicians 
in the sub-categorization of pruritus, i.e. by assessment 
of alloknesis, hyperknesis and response to pathway-
specific itch-induction, is warranted. Progress in these 
areas would prompt the mapping of chronic pruritus by 
pathological mechanism, which, in conjunction with 
well-planned clinical trials, could pave the way for 
improved treatment.
The authors declare no conflicts of interest.
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